Sales Force Effectiveness USA 2010

eyeforpharma17-18 May 2010, Princeton, NJ, USA.
SFE USA is a premier conference for pharma. Learn how to develop a winning sales strategy from pharma leaders. 10 Industry VPs will deliver sessions on healthcare reform, customer-centric models, and CRM tools.

SFE USA Program

Pharma In 2010 And Beyond

  • Lean, Mean, Switching machines- What is the future of Sales Force Effectiveness?
    Tony Fross, Senior Director WBB Business Excellence Group, Pfizer
  • Mergers & Acquisitions: What does the future hold?
    Richard Skelly, Senior Director Commercial Evaluations, AstraZeneca
  • Emerging Markets: Building BRIC(s) and Blocs
    Charlotte Sibley, Senior Vice President CBS Business Management, Shire
  • The future of pharma rests on the impending Health Care bill – be prepared and understand the implications
    Pharma Vice President confirmed, Genentech

Sales Excellence

  • Achieve more with less: Which commercial model will be most successful for your company?
    Barry Duke, Vice President Sales, Genzyme
  • Insights into Taro's commercial model strategies
    Joe Malta, Vice President Sales & Marketing, Taro Pharmaceuticals
  • The optimal size of your workforce: How small is big enough?
    Tracy Mills, Senior Director Sales Force Effectiveness, Endo Pharmaceuticals
  • Target managed markets and bring value to these powerful stakeholders
    Don Sawyer, Vice President Commercial Operations, AstraZeneca
  • How to ensure a long-term relationship with your key accounts
    Tony Zecca, Senior Director Sales Strategy, Effectiveness & Innovation, AstraZeneca

Sales Tools And Technology

  • Multi-Channel Management: Integrating promotion effectively across all channels
    Paulash Mohsen, VP Multichannel Marketing, Pfizer
  • Capitalise on the potential of e-detailing to reduce your marketing costs
    John Rotondo, VP & General Manager Commercial Operations, Bayer
  • Case Study: Closed Loop Marketing In A multi-channel environment
    Marc Valdiviezo, Director Marketing Excellence, Sanofi-Aventis
  • What technology should you provide your sales force to achieve optimum sales effectiveness?
    Edson Gemo, Senior Director Business Technology Sales Force Effectiveness Solution Center, Pfizer
    Steve Winawer, Senior Director, US Business Technology, Commercial Operations, Patient & Physician Marketing, Pfizer

Training And Development

  • The Evolution of Physician Behaviour and Implications for New Physician Access Models
    Mark Gleason, Senior Vice President, Corporate Development, Aptilon
  • SUPER PANEL: Scientist Vs salesman: Which approach will enable your sales reps to raise their value to the industry?
    Tim Ryan, Executive Director, Boehringer Ingelheim
    Christine Barczak, East Area Vice Presidnet, GSK
    Todd Lambert, Vice President Sales, Shire,
    Don Hribek, Senior Director of Strategic Accounts, EMD Serono
    Moderator: Greg Neal, Managing Partner, Rx Business Advantage Consulting
  • A sales force to be reckoned with: Transforming Sales Forces with talent upgrades, skills training, and business processes
    Joe Coffey, Vice President Sales, Baxter
  • Case Study: Discover the methodology behind successful training delivery
    Mike Capaldi, AVP Sales Training & Leadership Development, Sanofi-Aventis
  • Value Creation- The Next Frontier for Pharma
    Angela Bakker Lee, Principal, ZS Associates

For further information and registration, please visit:
http://www.eyeforpharma.com/sfeusa

Most Popular Now

Xenpozyme™ (olipudase alfa-rpcp) approved by FDA a…

The U.S. Food and Drug Administration (FDA) has approved Xenpozyme™ (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid...

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Research reveals widespread use of ineffective COV…

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

Efficacy, cash and more will increase booster shot…

The more effective the COVID-19 booster, the more likely people are to get it, according to new Cornell research. And they are more likely to accept the booster shot with...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...